Summary of Study ST001157
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000776. The data can be accessed directly via it's Project DOI: 10.21228/M8CH5C This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST001157 |
| Study Title | The gut microbiota plays a central role to modulate the plasma metabolome in response to chronic Angiotensin II infusion (part-I) |
| Study Summary | Six week old C57BL/6 conventional (mice with gut microbiota; conv, n=6) and germ-free (mice without gut microbiota; GF, n=6) mice were infused with angiotensin-II (AngII) for 4 weeks (400ng.kg-1.min-1; Alzet 1004). In parallel control groups, conv (n=6) and GF (n=6) mice received saline via minipumps. Our primary goal was to identify metabolites which were differentially regulated in conventional mice treated with AngII, but not in GF mice, indicating that these metabolites are microbial in origin. Following minipump implantation, animals were housed singly to prevent cross-contamination of microbiota. At the end of fourth week, feces and blood were collected. Both plasma and feces samples were processed and analyzed by using Liquid Chromatography-Tandem Mass Spectroscopy (LC-MS/MS) for metabolite detection (Metabolon). |
| Institute | Johns Hopkins University |
| Last Name | Pluznick |
| First Name | Jennifer |
| Address | 725 N. Wolfe St., WBSB 205, Baltimore, MD 21205 |
| jpluznick@jhmi.edu | |
| Phone | 410 614 4660 |
| Submit Date | 2019-03-20 |
| Raw Data Available | Yes |
| Analysis Type Detail | LC-MS |
| Release Date | 2019-05-15 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000776 |
| Project DOI: | doi: 10.21228/M8CH5C |
| Project Title: | The gut microbiota plays a central role to modulate the plasma metabolome in response to chronic Angiotensin II infusion |
| Project Summary: | Six week old C57BL/6 conventional (mice with gut microbiota; conv, n=6) and germ-free (mice without gut microbiota; GF, n=6) mice were infused with angiotensin-II (AngII) for 4 weeks (400ng.kg-1.min-1; Alzet 1004). In parallel control groups, conv (n=6) and GF (n=6) mice received saline via minipumps. Our primary goal was to identify metabolites which were differentially regulated in conventional mice treated with AngII, but not in GF mice, indicating that these metabolites are microbial in origin. Following minipump implantation, animals were housed singly to prevent cross-contamination of microbiota. At the end of fourth week, feces and blood were collected. Both plasma and feces samples were processed and analyzed by using Liquid Chromatography-Tandem Mass Spectroscopy (LC-MS/MS) for metabolite detection (Metabolon). |
| Institute: | Johns Hopkins University |
| Last Name: | Pluznick |
| First Name: | Jennifer |
| Address: | 725 N. Wolfe St., WBSB 205, Baltimore, MD 21205 |
| Email: | jpluznick@jhmi.edu |
| Phone: | 410 614 4660 |
Subject:
| Subject ID: | SU001222 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Gender: | Male and female |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Sample |
|---|---|---|
| SA080318 | JHOP-05707 | Plasma | TREATMENT:Angiotensin II |
| SA080319 | JHOP-05706 | Plasma | TREATMENT:Angiotensin II |
| SA080320 | JHOP-05708 | Plasma | TREATMENT:Angiotensin II |
| SA080321 | JHOP-05716 | Plasma | TREATMENT:Angiotensin II |
| SA080322 | JHOP-05715 | Plasma | TREATMENT:Angiotensin II |
| SA080323 | JHOP-05705 | Plasma | TREATMENT:Angiotensin II |
| SA080324 | JHOP-05704 | Plasma | TREATMENT:Angiotensin II |
| SA080325 | JHOP-05720 | Plasma | TREATMENT:Angiotensin II |
| SA080326 | JHOP-05719 | Plasma | TREATMENT:Angiotensin II |
| SA080327 | JHOP-05718 | Plasma | TREATMENT:Angiotensin II |
| SA080328 | JHOP-05703 | Plasma | TREATMENT:Angiotensin II |
| SA080329 | JHOP-05717 | Plasma | TREATMENT:Angiotensin II |
| SA080330 | JHOP-05714 | Plasma | TREATMENT:Saline |
| SA080331 | JHOP-05713 | Plasma | TREATMENT:Saline |
| SA080332 | JHOP-05709 | Plasma | TREATMENT:Saline |
| SA080333 | JHOP-05700 | Plasma | TREATMENT:Saline |
| SA080334 | JHOP-05699 | Plasma | TREATMENT:Saline |
| SA080335 | JHOP-05698 | Plasma | TREATMENT:Saline |
| SA080336 | JHOP-05701 | Plasma | TREATMENT:Saline |
| SA080337 | JHOP-05702 | Plasma | TREATMENT:Saline |
| SA080338 | JHOP-05711 | Plasma | TREATMENT:Saline |
| SA080339 | JHOP-05710 | Plasma | TREATMENT:Saline |
| SA080340 | JHOP-05697 | Plasma | TREATMENT:Saline |
| SA080341 | JHOP-05712 | Plasma | TREATMENT:Saline |
| Showing results 1 to 24 of 24 |
Collection:
| Collection ID: | CO001216 |
| Collection Summary: | Plasma |
| Collection Protocol Filename: | Sample_Collection-Feces_Pluznick.pdf |
| Sample Type: | Blood (serum) |
Treatment:
| Treatment ID: | TR001237 |
| Treatment Summary: | Six week old C57BL/6 conventional (mice with gut microbiota; conv, n=6) and germ-free (mice without gut microbiota; GF, n=6) mice were infused with angiotensin-II (AngII) for 4 weeks (400ng.kg-1.min-1; Alzet 1004). In parallel control groups, conv (n=6) and GF (n=6) mice received saline via minipumps. |
| Treatment Protocol Filename: | Treatment_Protocol__Pluznick.pdf |
Sample Preparation:
| Sampleprep ID: | SP001230 |
| Sampleprep Summary: | Samples were prepared using the automated MicroLab STAR® system from Hamilton Company. Several recovery standards were added prior to the first step in the extraction process for QC purposes. To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The resulting extract was divided into five fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved for backup. Samples were placed briefly on a TurboVap® (Zymark) to remove the organic solvent. The sample extracts were stored overnight under nitrogen before preparation for analysis. |
Combined analysis:
| Analysis ID | AN001915 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Waters Acquity |
| Column | Waters Acquity CSH C18 (100 x 2.1mm,1.7um) |
| MS Type | ESI |
| MS instrument type | Orbitrap |
| MS instrument name | Thermo Q Exactive Orbitrap |
| Ion Mode | NEGATIVE |
| Units | Peaks area |
Chromatography:
| Chromatography ID: | CH001388 |
| Methods Filename: | Ultrahigh_Performance_LC_Method_Pluznick.pdf |
| Instrument Name: | Waters Acquity |
| Column Name: | Waters Acquity CSH C18 (100 x 2.1mm,1.7um) |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS001771 |
| Analysis ID: | AN001915 |
| Instrument Name: | Thermo Q Exactive Orbitrap |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | None |
| Ion Mode: | NEGATIVE |
